

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Comparison of a Target Trial Emulation Framework to Cox Regression to Estimate the Effect of Corticosteroids on COVID-19 Mortality

Katherine L. Hoffman, MS¹
Edward J. Schenck, MD, MS²
Michael J. Satlin, MD³
William Whalen, MD, MS²,
Di Pan, MD, MS²
Nicholas Williams, MPH⁴
Iván Díaz, PhD¹

¹Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.

²Division of Pulmonary and Critical Care, Department of Medicine, Weill Cornell Medicine, New York, NY.

³Division of Infectious Disease, Department of Medicine, Weill Cornell Medicine, New York, NY.

⁴Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.

August 9, 2022

2,993 words

36

Key Points

37 **Question:** How do modern methods for causal inference compare to approaches common in the
38 clinical literature when estimating the effect of corticosteroids on mortality for moderate-to-
39 severe coronavirus disease 2019 (COVID-19) patients?

40 **Findings:** In an analysis using retrospective data for 3,298 hospitalized COVID-19 patients,
41 target trial emulation using a doubly robust estimation procedure successfully recovers a
42 randomized controlled trial (RCT) meta-analysis benchmark. In contrast, analytic approaches
43 common in the clinical research literature generally cannot recover the benchmark.

44 **Meaning:** Clinical research based on observational data can unveil true causal relations.
45 However, the correctness of these effect estimates requires designing and analyzing the data
46 based on principles which are different from the current standard in clinical research. Widespread
47 communication and adoption of these analytical techniques are of high importance for the
48 improvement of clinical research.

49

50

51

Abstract

52 **Importance:** Communication and adoption of modern study design and analytical techniques is
53 of high importance for the improvement of clinical research from observational data.

54 **Objective:** To compare (1) a modern method for causal inference including a target trial
55 emulation framework and doubly robust estimation to (2) approaches common in the clinical
56 literature such as Cox proportional hazards models. To do this, we estimate the effect of
57 corticosteroids on mortality for moderate-to-severe coronavirus disease 2019 (COVID-19)
58 patients. We use the World Health Organization's (WHO) meta-analysis of corticosteroid
59 randomized controlled trials (RCTs) as a benchmark.

60 **Design:** Retrospective cohort study using longitudinal electronic health record data for 28 days
61 from time of hospitalization.

62 **Settings:** Multi-center New York City hospital system.

63 **Participants:** Adult patients hospitalized between March 1-May 15, 2020 with COVID-19 and
64 not on corticosteroids for chronic use.

65 **Intervention:** Corticosteroid exposure defined as $>0.5\text{mg/kg}$ methylprednisolone equivalent in a
66 24-hour period. For target trial emulation, interventions are (1) corticosteroids for six days if and
67 when patient meets criteria for severe hypoxia and (2) no corticosteroids. For approaches
68 common in clinical literature, treatment definitions used for variables in Cox regression models
69 vary by study design (no time frame, one-, and five-days from time of severe hypoxia).

70 **Main outcome:** 28-day mortality from time of hospitalization.

71 **Results:** 3,298 patients (median age 65 (IQR 53-77), 60% male). 423 receive corticosteroids at
72 any point during hospitalization, 699 die within 28 days of hospitalization. Target trial emulation
73 estimates corticosteroids to reduce 28-day mortality from 32.2% (95% CI 30.9-33.5) to 25.7%
74 (24.5-26.9). This estimate is qualitatively identical to the WHO's RCT meta-analysis odds ratio
75 of 0.66 (0.53-0.82)). Hazard ratios using methods comparable to current corticosteroid research
76 range in size and direction from 0.50 (0.41-0.62) to 1.08 (0.80-1.47).

77 **Conclusion and Relevance:** Clinical research based on observational data can unveil true causal
78 relationships; however, the correctness of these effect estimates requires designing the study and
79 analyzing the data based on principles which are different from the current standard in clinical
80 research.

81

82

83

84

85

86 **Introduction**

87 Observational databases are invaluable resources when randomized controlled trials (RCTs) are
88 infeasible or unavailable. However, the correctness of the conclusions gleaned from analyses of
89 observational data hinges on the careful consideration of study design principles and choice of
90 estimation methodology.¹⁻⁴

91 In this paper we contrast the use of target trial emulation using contemporary causal inference
92 methods with various traditional analytical approaches using Cox regression. While most
93 epidemiologists and statisticians agree on the importance of a well-defined exposure, outcome,
94 and population of interest, the two strategies we compare differ significantly in the subsequent
95 steps to choose a research question and data analysis method.

96 In the traditional approach to clinical research, the analysis proceeds by postulating a
97 regression model according to the type of data available. For example, when faced with a time-
98 to-event outcome, researchers automatically fit a Cox regression model (often due to limitations
99 in knowledge, time, or software capabilities). The coefficients of the regression model are then
100 used to answer to the clinical question of interest. We refer to this approach as a “model-first”
101 approach, due to the primacy of the regression model.

102 A model-first approach induces multiple problems for the estimation of causal effects.⁵ First,
103 regression coefficients often do not represent quantities of primary scientific interest or well-
104 defined causal effects.⁶ Second, assumptions such as the proportional hazards assumption used in
105 Cox models are rarely correct in medical research, since hazards cannot be proportional when a
106 treatment effect changes over time.⁷ Third, regression models cannot correctly handle time-
107 dependent feedback between confounders, treatment, and the outcome.¹ Fourth, the model-first
108 approach yields a tendency to interpret all coefficients in the model; a problem known as the

109 Table 2 fallacy.⁸ Lastly, model-first approaches fail to account for the variance induced during
110 model selection, thereby leading to incorrect statistical conclusions.⁹

111 Recent developments in the causal inference literature provide researchers with a number of
112 tools to alleviate the aforementioned biases. Frameworks such as the target trial emulation¹⁰ and
113 roadmap for causal inference¹¹ allow researchers to proceed with a *question-first* approach.
114 Instead of defaulting to effect measures provided by regression models, a question-first approach
115 begins by defining a hypothetical target trial and subsequent target of inference that answers the
116 scientific question of interest. This is the so-called estimand, or quantity to be estimated. After
117 the estimand is chosen, researchers have the freedom to select an estimation technique which
118 mitigates model misspecification biases. Incorporating these principles can help clarify the
119 research question, determine study eligibility requirements, identify enrollment and follow-up
120 times, decide whether sufficient confounder data are available, increase the likelihood of
121 obtaining a correct estimate, and more.^{12,13}

122 In this study, we compare a question-first approach against multiple model-first approaches
123 for causal inference. Our case study is the effect of corticosteroids on mortality for moderate-to-
124 severe COVID-19 patients using a retrospective cohort of patients at NewYork-Presbyterian
125 Hospital (NYPH) during Spring 2020. Lack of guidance for clinical practice at the beginning of
126 the pandemic meant that high variability existed in the administration and timing of
127 corticosteroids (eFigure 1). Provider practice variability aids in the estimation of causal effects by
128 yielding datasets with adequate natural experimentation, but the resulting complex longitudinal
129 treatment patterns complicate study design and analytical methods. This observational dataset
130 together with results from numerous RCTs on corticosteroids provides a unique opportunity to

131 benchmark design and analysis methods. We benchmark our target trial emulation results against
132 effect measures obtained in the World Health Organization (WHO)'s RCT meta-analysis.¹⁴

133 **Methods**

134 This study was designed in April 2020, prior to the results of corticosteroid RCTs and resulting
135 clinical guidance. It was approved by the Institutional Review Board at Weill Cornell Medicine
136 with a waiver of informed consent (no. 20-04021909). This report follows the Strengthening the
137 Reporting of Observational Studies in Epidemiology (STROBE) guidelines.¹⁵

138

139 **Hypothetical target trial**

140 **Question**

141 What is the effect of a treatment regime of corticosteroids administered under the clinical
142 indication of severe hypoxia on mortality for COVID-19 hospitalized patients?

143 **Population**

144 Inclusion criteria is adult COVID-19 positive patients who were admitted to NYPH's Cornell,
145 Lower Manhattan, or Queens locations. Cases are confirmed through reverse-transcriptase–
146 polymerase chain-reaction assays performed on nasopharyngeal swab specimens. The tests are
147 obtained upon hospital admission, i.e., at the same time of eligibility and time zero. Patients who
148 have chronic use of corticosteroids prior to hospitalization or who are transferred into NYPH
149 from an outside hospital are excluded.

150 **Hypothetical treatment regime**

151 Patients would be randomized on their first day of hospitalization to receive either (1) standard of
152 care therapy (without corticosteroids) or (2) standard of care plus a corticosteroid regimen to be
153 administered if and when criteria for severe hypoxia are met. The corticosteroid dosage is a
154 minimum of 0.5 mg/kg body weight of methylprednisolone equivalent per 24-hour period and
155 the duration of therapy is six days.¹⁶ Corticosteroids include prednisone, prednisolone,
156 methylprednisolone, hydrocortisone, and dexamethasone and choice of drug is at the attending
157 physician's discretion. Severe hypoxia is defined as the initiation of high-flow nasal cannula,
158 venti-mask, noninvasive or invasive mechanical ventilation, or an oxygen saturation of <93%
159 after the patient is on 6 Liters of supplemental oxygen via nasal cannula.

160 **Outcome and estimand**

161 The primary outcome would be 28-day mortality from time of randomization. The contrast of
162 interest is the 28-day mortality rate difference comparing actual receipt of the two treatment
163 regimes (i.e., the per-protocol effect).

164 **Data analysis plan**

165 A hypothetical trial can assume no loss-to-follow-up. Under perfect compliance we would
166 analyze the difference in proportion of patients who experienced the outcome between the two
167 treatment regimes.

168 **Emulation using observational data**

169 **Data source and cohort**

170 The target trial emulation uses retrospective data from patients who meet the hypothetical trial's
171 eligibility criteria March 1-May 15, 2020. Demographic, comorbidity, and outcome data were
172 manually abstracted by trained medical professionals into a secure REDCap database.¹⁷ These
173 were supplemented with an internal COVID data repository housing laboratory, procedure,
174 medication, and flowsheet data documented during standard care.¹⁸ Patients are followed for 28
175 days from hospitalization and lost to follow-up by discharge or transfer to an external hospital
176 system.

177 **Treatment regimes and measurement**

178 To emulate the target trial corticosteroid treatment regime, we estimate the effect of a
179 hypothetical dynamic treatment regime,¹⁹ whereby each patient is administered six days of
180 corticosteroids if and when they meet severe hypoxia criteria. This dynamic regime is contrasted
181 with a static regime where patients never receive corticosteroids.

182 We measure severe hypoxia using vital signs and flowsheet data and define it in the same
183 way as our target trial. We measure corticosteroid exposure using the medication administration
184 record. We compute cumulative mg/kg dosing of corticosteroids over rolling 24-hour windows,
185 and if a patient received >0.5 mg/kg methylprednisolone equivalent, they are denoted as having
186 corticosteroids exposure that day.

187 Since patients in the observed data are subject to loss-to-follow-up, emulating the trial with
188 observational data requires conceptualizing a hypothetical world where all patients are observed
189 through 28 days. Effects in this hypothetical world can be estimated using observed patient data

190 under assumptions articulated in the *Data Analysis* section. An illustration of the treatment
191 regimes as they relate to the observed data are shown in Figure 1.

192 **Confounding**

193 In contrast to the hypothetical trial, treatment assignment in the observational study is not
194 randomized and depends on physiological characteristics of each patient. We address
195 confounding in our emulation by adjustment for confounders during data analysis. A set of
196 confounders deemed sufficient for adjustment was determined through the expertise of a team of
197 pulmonologists, intensivists, and microbiologists.

198 Baseline confounders include socio-demographics, Body Mass Index (BMI), comorbidities,
199 and hospital admission location. Time-dependent confounders include vital signs, laboratory
200 results, co-treatments, and mode of respiratory support. The measurement process (i.e., whether a
201 clinician decided to measure these variables) is also an important confounder included in the
202 analysis. Details of confounders are provided in eMethods. Figure 2 summarizes the relationship
203 between confounders, treatment, and outcomes in the form of a Directed Acyclic Graph.

204 **Outcome and estimand**

205 Our estimand of interest is the difference in 28-day mortality rates in a hypothetical world
206 where we had implemented the two different corticosteroid treatment regimes, as well as an
207 intervention to prevent loss-to-follow-up. Under the assumption that treatment and loss-to-
208 follow-up each day are randomized conditional on the baseline and time-dependent confounders,
209 this estimand is identifiable by a longitudinal g-computation formula.²⁰ It is important to
210 emphasize that conditional randomization is a key assumption without which the target

211 emulation may fail. This g-formula will be our estimand of interest, but we note that it is not the
212 only possible identification strategy (see eMethods).

213 **Data analysis plan**

214 When using the g-formula to identify causal effects, correct emulation of a target trial
215 requires proper adjustment for measured confounding. It is important to use estimation methods
216 capable of fitting the data using flexible mathematical relationships so that confounding is
217 appropriately removed, especially when the number of baseline and time-dependent confounders
218 is large.

219 Methods to estimate the g-computation formula (e.g., inverse probability weighting (IPW),
220 parametric g-formula, targeted minimum loss-based estimators (TMLE), sequentially doubly
221 robust estimators (SDR), etc.)^{21,22} rely on two kinds of mathematical models: (i) the outcome as a
222 function of the time-dependent confounders, and (ii) treatment as a function of time-dependent
223 confounders. Methods that use only one of these models are often called *singly robust*, because
224 their correctness relies on the ability to correctly specify one of the models (e.g., IPW relies on
225 estimating treatment models correctly). Methods that use both of these models are often called
226 *doubly robust*, because they remain correct under misspecification of one of the two models.

227 Furthermore, doubly robust estimators such as TMLE and SDR allow the use of machine
228 learning to flexibly fit relevant treatment and outcome regressions.^{23,24} This is desirable because
229 these regression functions might include complex relationships, and capturing those relationships
230 is not possible using simpler regression such as the Cox model.²⁵

231 The primary analysis is conducted using SDR estimation with a dynamic intervention, time-
232 varying confounders, and a time-to-event outcome. An ensemble of machine learning models
233 using the super learner algorithm is used to estimate the regressions for treatment and

234 outcome.^{26,27} Additional details, including sensitivity analyses, an illustrated analytical file
235 (eFigure 2), and code tutorial, are available in eMethods.

236 **Model-first approaches**

237 For contrast with the target trial emulation strategy, we review methodology of papers cited in
238 Chaharom et al.'s²⁸ COVID-19 corticosteroids meta-analysis, and then analyze the data using
239 study designs common in those papers. The data source and outcome are the same as the above
240 target trial. Modifications to the cohort, confounders, and treatment definitions to accommodate
241 the model-first approaches are outlined below.

242 **Point-treatment Cox models**

243 The first approach we explore is a regression for mortality with a point-treatment variable. The
244 inclusion criteria and time zero are defined as the time of meeting hypoxia criteria, which is the
245 intended indication for corticosteroids. A study design using this approach entails several
246 choices, including defining a range of time relative to inclusion criteria for a patient to be
247 considered “treated”. Once this range is determined, researchers must decide how to handle
248 patients treated before the inclusion time begins or after the treatment interval ends, as well as
249 those who experience the outcome within the treatment interval.

250 We fit Cox models using data sets obtained from various design choices, summarized in
251 Table 1. Baseline confounders and time-dependent confounders from day zero are included as
252 adjustment variables. The exponentiated coefficient for corticosteroids is interpreted as the
253 hazard ratio for corticosteroid exposure within the defined treatment window for moderate-to-
254 severe COVID-19 patients.

255 These point-treatment estimates apply only to the hypoxic population. They are different
256 from the effects in the target trial emulation, which apply to the population of hospitalized
257 patients. These effects are the closest possible analog we can obtain within a model-first
258 framework using a point-treatment.

259 **Time-varying Cox models**

260 In the second model-first approach, we fit a time-varying Cox model for time to mortality up to
261 28 days from the day of hospitalization. This model uses the entire cohort and contains baseline
262 and time-dependent confounders, as well as daily corticosteroid administration. The coefficient
263 for corticosteroids is exponentiated and used as an estimate of the hazard ratio for corticosteroids
264 on mortality in hospitalized COVID-19 patients.

265 **RCT benchmark**

266 Several RCTs have established the effectiveness of corticosteroids in the treatment of moderate-
267 to-severe COVID-19 patients.²⁹⁻³¹ The WHO performed a meta-analysis of seven such RCTs and
268 estimated the OR of mortality to be 0.66 (95% CI 0.53-0.82).¹⁴ We use this estimate, as well as
269 supporting evidence from other RCT meta-analyses^{28,32} to benchmark our results. A discussion of
270 assumptions for benchmarking, along with comparisons of our target trial study design,
271 population, and treatment arms to the benchmark RCTs (eTables 1-3), is provided in the
272 Appendix.

273 **Results**

274 **Target trial emulation**

275 In the target trial emulation analysis, all 3,298 patients who were admitted to the hospital are
276 analyzed. Table 2 and eTable 4 display characteristics of the cohort, and eTable 5 describes the
277 informative measurement process. There were 1,690 patients who reached severe hypoxia and
278 423 patients who received corticosteroids at any point during follow-up. 699 patients died before
279 28 days.

280 The estimated mortality rate under our no corticosteroids regime is 32.2% (95% CI 30.9-
281 33.5). The estimated mortality rate under our corticosteroids regime is 25.7% (24.5-26.9). This
282 yields an estimated mortality reduction of 6.5% (5.7-7.4) if this policy had been implemented.
283 Sensitivity analyses (see Appendix) yield near-identical results.

284 **Model-first approaches**

285 In the subset of patients who met severe hypoxia, 72 patients received corticosteroids within one
286 day of hypoxia and 191 patients received corticosteroids within 5 days of hypoxia. There were 18
287 and 451 patients who died within one and five days of hypoxia without receiving corticosteroids,
288 respectively.

289 Model A, which defined corticosteroid exposure as anytime during hospitalization, yielded an
290 HR of 0.50 (0.41-0.62). Models B-I, which placed either a one- or five-day limit on
291 corticosteroids treatment from the time of hypoxia, yielded mostly non-significant HRs in both
292 directions (B: 0.95 (0.66-1.37), C: 0.92 (0.63-1.33), D: 0.89 (0.56-1.41), E: 0.66 (0.41-1.04), G:
293 1.05 (0.77-1.45), H: 1.04 (0.75-1.45)). The exception to this was Model I, which excluded

294 patients who died before five days and estimated the HR to be 0.63 (0.48-0.83). Model F also
295 reached statistical significance, 0.77 (0.60-0.99), and was the result of a 5-day treatment window
296 with no exclusion or censoring variations. The time-varying Cox model yielded an HR of 1.08
297 (0.80-1.47). Figure 3 summarizes the model-first results.

298 **Discussion**

299 Our research illustrates how a question-first approach can aid in devising an optimal design and
300 choice of estimation procedure for an analysis of observational data. We show that using the
301 target trial framework succeeds in recovering the benchmark causal effect obtained in RCTs. Our
302 estimate that corticosteroids would reduce overall 28-day mortality in a hospitalized cohort is
303 equivalent to an OR of 0.73 (0.68-.74), which is qualitatively identical to the WHO’s estimate of
304 0.66 (0.53-0.82). Our study design allowed us to conceptualize a meaningful intervention, i.e.,
305 randomize patients at hospitalization but do not give corticosteroids unless the patient becomes
306 severely hypoxic. Our analysis plan enabled us to flexibly adjust for a large number of potential
307 time-dependent confounders.

308 In contrast, the majority of the model-first approaches could not recover the RCT benchmark
309 using the same data source. This finding aligns with other corticosteroids research; a recent meta-
310 analysis containing observational analyses on over 18,000 patients found no overall effect for
311 corticosteroids on mortality (OR 1.12, (0.83–1.50)).²⁸ The task of creating reliable evidence from
312 complex longitudinal data is not an easy one, and many of these studies suffer from flawed
313 designs.

314 We found most studies in the current observational corticosteroids literature allowed the
315 “treated” group to receive corticosteroids anytime during hospitalization.³³⁻³⁵ This is problematic

316 because it introduces immortal time and biases results towards a protective effect of
317 corticosteroids.³⁵ A few studies did limit the treatment time frame in an effort to diminish
318 immortal time bias. The “grace period” for treatment was handled in various ways, e.g. excluding
319 patients who die prior to a time window after inclusion criteria,³⁷ or excluding patients who
320 receive treatment after the treatment window ends.^{38,39} Both exclusions may lead to bias and
321 spurious associations.¹ An alternative to exclusion is censoring patients at their time of receiving
322 treatment if that time is after the treatment window passes, however, Cox regression cannot
323 handle time-dependent censoring.¹

324 In addition to these issues, it is often unclear in the current literature how patients who
325 receive corticosteroids prior to meeting inclusion criteria are handled in the analysis.^{33-35,40} A
326 related issue is that corticosteroids can affect severity of illness. All of the point-treatment studies
327 are thus subject to collider bias by subsetting to severely ill patients.⁴¹ While the time-varying
328 Cox approach does not suffer from the same time-alignment biases as the point-treatment design,
329 it cannot properly account for time-dependent confounders.¹ These biases appear in our model-
330 first results; the study designs which result in a statistically significant protective effect of
331 corticosteroids suffer from extreme immortal time bias through undefined or extended treatment
332 time windows (A,F,I).

333

334 ***Limitations***

335 First, while the pre-RCT study time frame is ideal for natural experimentation and the estimation
336 of causal effects, it includes surge conditions and rapidly changing clinical practice, challenging
337 the assumptions needed for transportability and benchmarking. Second, we cannot rule out
338 unmeasured confounding in the treatment, censoring, or outcome mechanisms. Specifically, the
339 different discharge pathways (home, nursing home, etc.) may be associated to unmeasured

340 patient characteristics and lead to very different outcomes. Third, we did not have the data to
341 look at individual corticosteroid types, making comparisons to a specific RCT impossible.
342 Fourth, the binning of our data into 24-hour intervals may induce issues related to the correct
343 time-ordering of events (see Appendix).

344

345 *Conclusions*

346 This study serves as an example in which the current standard for clinical research methods
347 fails to recover the correct treatment effect where a modern causal inference method succeeds.
348 Using observational data to guide clinical practice is possible but relies on the use of
349 contemporary statistical and epidemiological principles. We hope this study and accompanying
350 technical guide encourages adoption of similar innovative techniques into study designs and
351 statistical analyses for observational medical research.

352

353

354

355

356 **Acknowledgements**

357 The authors thank all of the healthcare workers who courageously expanded their roles during the
358 pandemic's surge conditions. This work was made possible through data provided by the Cornell
359 COVID-19 Registry, led by Parag G. Goyal, M.D., Justin Choi, M.D., Laura Pinheiro, Ph.D., and
360 Monika Safford, M.D., of Weill Cornell Medicine. The authors would like to acknowledge the
361 chart abstractors, which included a team of Weill Cornell Medicine medical students and
362 NewYork-Presbyterian/Weill Cornell Medical Center house staff. The authors also thank the
363 contributions to this work of the Architecture for Research Computing in Health team.

364

365 **Author contributions:** Katherine L. Hoffman, M.S. had full access to all the data in the study
366 and takes responsibility for the integrity of the data and the accuracy of the data analysis.

367 **Conflict of Interest Disclosures:** Dr. Edward Schenck is supported by NHLBI HL151876 and
368 reports consulting for Axle Informatics regarding Coronavirus vaccine clinical trial through
369 NIAID and receiving honoraria from American Thoracic Society outside of the current work. Dr.
370 Michael Satlin is supported by research grants from Allergan, Merck, BioFire Diagnostics, and
371 SNIPRBiome and reports consulting payments from Shionogi outside of the current work.

372 **Funding/Support:** This study did not receive any funding.

373

374

375 References

- 376 [1] Robins JM Hernán MA. *Causal Inference: What If*. Boca Raton: Chapman & Hall; 2020.
- 377 [2] Miguel A. Hernán. Methods of public health research — strengthening causal inference
378 from observational data. *New England Journal of Medicine*. 2021; 385(15):1345–1348. doi:
379 10.1056/NEJMp2113319. URL <https://doi.org/10.1056/NEJMp2113319>. PMID: 34596980.
- 380 [3] Steven S. Henley, Richard M. Golden, and T. Michael Kashner. Statistical modeling
381 methods: challenges and strategies. *Biostatistics & Epidemiology*. 2020;4(1):105–139. doi:
382 10.1080/24709360.2019.1618653. URL <https://doi.org/10.1080/24709360.2019.1618653>.
- 383 [4] Mohammad Ali Mansournia, Mahyar Etminan, Goodarz Danaei, Jay S Kaufman, and Gary
384 Collins. Handling time varying confounding in observational research. *BMJ*. 2017;359.
385 ISSN 0959-8138. doi: 10.1136/bmj.j4587. URL [https://www.bmj.com/content/359/
386 bmj.j4587](https://www.bmj.com/content/359/bmj.j4587).
- 387 [5] Leo Breiman. Statistical modeling: The two cultures (with comments and a rejoinder by the
388 author). *Statistical science*. 2001;16(3):199–231.
- 389 [6] Miguel A. Hernán. The Hazards of Hazard Ratios. *Epidemiology*. 2010;21(1):13–15, 01.
390 doi: 10.1097/EDE.0b013e3181c1ea43.
- 391 [7] Mats J. Stensrud and Miguel A. Hernán. Why Test for Proportional Hazards? *JAMA*. 2020;
392 323 (14):1401–1402, 04. ISSN 0098-7484. doi: 10.1001/jama.2020.1267. URL [https:
393 //doi.org/10.1001/jama.2020.1267](https://doi.org/10.1001/jama.2020.1267).
- 394 [8] Daniel Westreich and Sander Greenland. The Table 2 Fallacy: Presenting and Interpreting
395 Confounder and Modifier Coefficients. *American Journal of Epidemiology*.
396 2013;177(4):292–298, 01. ISSN 0002-9262. doi: 10.1093/aje/kws412. URL
397 <https://doi.org/10.1093/aje/kws412>.
- 398 [9] Gary Smith. Step away from stepwise. *Journal of Big Data*. 2018; 5(1):1–12.
399 <https://doi.org/10.1186/s40537-018-0143-6>
- 400 [10] Miguel A. Hernán and James M. Robins. Using Big Data to Emulate a Target Trial When a
401 Randomized Trial Is Not Available. *American Journal of Epidemiology*. 2016;183(8):758–
402 764, 03. ISSN 0002-9262. doi: 10.1093/aje/kwv254. URL [https://doi.org/10.1093/
403 aje/kwv254](https://doi.org/10.1093/aje/kwv254).
- 404 [11] Maya L. Petersen and Mark J. van der Laan. Causal models and learning from data:
405 Integrating causal modeling and statistical estimation. *Epidemiology*. 2014;25(3):418–426.
406 ISSN 10443983. URL <http://www.jstor.org/stable/24759134>.
- 407 [12] Jeremy A Labrecque and Sonja A Swanson. Target trial emulation: teaching epidemiology
408 and beyond. *European journal of epidemiology*. 2017;32(6):473–475.

- 409 [13] Miguel A. Hernán, Brian C. Sauer, Sonia Hernández-Díaz, Robert Platt, and Ian Shrier.
410 Specifying a target trial prevents immortal time bias and other self-inflicted injuries in
411 observational analyses. *Journal of Clinical Epidemiology*. 2016;79:70–75. ISSN 0895-
412 4356. doi: <https://doi.org/10.1016/j.jclinepi.2016.04.014>. URL
413 <https://www.sciencedirect.com/science/article/pii/S0895435616301366>.
- 414 [14] Jonathan AC Sterne, Srinivas Murthy, Janet V Diaz, Arthur S Slutsky, Jesús Villar, Derek
415 C Angus, et al. Association between administration of systemic corticosteroids and
416 mortality among critically ill patients with covid-19: a meta-analysis. *Jama*. .
417 2020;324(13):1330–1341.
- 418 [15] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE
419 Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology
420 (STROBE)statement: guidelines for reporting observational studies.
421 *J Clin Epidemiol*. 2008 Apr;61(4):344-9. PMID: 18313558
- 422 [16] Steroid conversion calculator. URL [https://www.mdcalc.com/steroid-](https://www.mdcalc.com/steroid-conversion-calculator)
423 [conversion-calculator](https://www.mdcalc.com/steroid-conversion-calculator). Accessed May 10, 2020.
- 424 [17] Parag Goyal, Justin J Choi, Laura C Pinheiro, Edward J Schenck, Ruijun Chen, Assem
425 Jabri, et al. Clinical characteristics of covid-19 in new york city. *New England Journal of*
426 *Medicine*. 2020;382(24): 2372–2374.
- 427 [18] Edward J Schenck, Katherine L Hoffman, Marika Cusick, Joseph Kabariti, Evan T Sholle,
428 and Thomas R Champion Jr. Critical care database for advanced research (cedar): An
429 automated method to support intensive care units with electronic health record data. *Journal*
430 *of Biomedical Informatics*. 2021;118:103789.
- 431 [19] Bibhas Chakraborty and EE Moodie. Statistical methods for dynamic treatment regimes.
432 *Springer-Verlag*. 2013. doi, 10:978–1.
- 433 [20] James Robins. A new approach to causal inference in mortality studies with a sustained
434 exposure period—application to control of the healthy worker survivor effect.
435 *Mathematical Modelling*. 1986;7(9):1393–1512. ISSN 0270-0255. doi:
436 [https://doi.org/10.1016/0270-0255\(86\)90088-6](https://doi.org/10.1016/0270-0255(86)90088-6). URL
437 <https://www.sciencedirect.com/science/article/pii/0270025586900886>.
- 438 [21] Alexander R Luedtke, Oleg Sofrygin, Mark J van der Laan, and Marco Carone. Sequential
439 double robustness in right-censored longitudinal models. *arXiv preprint arXiv*.
440 2017;1705.02459.
- 441 [22] Iván Díaz, Nicholas Williams, Katherine L. Hoffman, and Edward J. Schenck.
442 Nonparametric causal effects based on longitudinal modified treatment policies. *Journal of*
443 *the American Statistical Association*. 2021;0(0):1–16. doi:
444 10.1080/01621459.2021.1955691. URL <https://doi.org/10.1080/01621459.2021.1955691>.

- 445 [23] Mark J. van der Laan and Sherri Rose. *Targeted Learning in Data Science: Causal*
446 *Inference for Complex Longitudinal Studies*. Springer Publishing Company, Incorporated,
447 1st edition, 2018. ISBN 3319653032.
- 448 [24] Victor Chernozhukov, Denis Chetverikov, Mert Demirer, Esther Duflo, Christian Hansen,
449 Whitney Newey, et al. Double/debiased machine learning for treatment and structural
450 parameters. *The Econometrics Journal*. 2018;21(1):C1–C68, 01. ISSN 1368-4221. doi:
451 10.1111/ectj.12097. URL <https://doi.org/10.1111/ectj.12097>.
- 452 [25] T. A. Gerds and M. Schumacher. On functional misspecification of covariates in the Cox
453 regression model. *Biometrika*. 2001;88(2):572–580, 06. ISSN 0006-3444. doi: 10.1093/
454 biomet/88.2.572. URL <https://doi.org/10.1093/biomet/88.2.572>.
- 455 [26] Leo Breiman. Stacked regressions. *Machine learning*. 1996;24(1):49–64.
- 456 [27] Mark J. van der Laan, Eric C Polley, and Alan E. Hubbard. Super learner. *Statistical*
457 *Applications in Genetics and Molecular Biology*. 2007;6(1). doi: doi:10.2202/1544-
458 6115.1309. URL <https://doi.org/10.2202/1544-6115.1309>.
- 459 [28] Faegheh Ebrahimi Chaharom, Leili Pourafkari, Ali Asghar Ebrahimi Chaharom, and Nader
460 D Nader. Effects of corticosteroids on covid-19 patients: A systematic review and meta-
461 analysis on clinical outcomes. *Pulmonary pharmacology & therapeutics*, 2021;page 102-
462 107.
- 463 [29] Bruno Martins Tomazini, Israel Silva Maia, Flavia Regina Bueno, Maria Vitoria Aparecida
464 Oliveira Silva, Franca Pellison Baldassare, et al. Covid-19-associated ards treated with
465 dexamethasone (codex): study design and rationale for a randomized trial. *Revista*
466 *Brasileira de terapia intensiva*. 2020;32:354–362.
- 467 [30] Maryam Edalatifard, Maryam Akhtari, Mohammadreza Salehi, Zohre Naderi, Ahmadreza
468 Jamshidi, Shayan Mostafaei, et al. Intravenous methylprednisolone pulse as a treatment for
469 hospitalised severe covid-19 patients: results from a randomised controlled clinical trial.
470 *European Respiratory Journal*. 2020;56(6).
- 471 [31] Luis Corral-Gudino, Alberto Bahamonde, Francisco Arnaiz-Revillas, Julia Gómez-
472 Barquero, Jesica Abadía-Otero, Carmen García-Ibarbia, et al. Methylprednisolone in adults
473 hospitalized with covid-19 pneumonia. *Wiener klinische Wochenschrift*. 2021;133(7):303–
474 311.
- 475 [32] Carina Wagner, Mirko Griesel, Agata Mikolajewska, Anika Mueller, Monika Nothacker,
476 Karoline Kley, et al. Systemic corticosteroids for the treatment of covid-19. *Cochrane*
477 *Database of Systematic Reviews*. 2021;(8).
- 478 [33] Ana Fernández-Cruz, Belén Ruiz-Antorán, Ana Muñoz-Gómez, Aránzazu Sancho-López,
479 Patricia Mills-Sánchez, Gustavo Adolfo Centeno-Soto, et al. A retrospective con- trolled
480 cohort study of the impact of glucocorticoid treatment in sars-cov-2 infection mortality.
481 *Antimicrobial agents and chemotherapy*, 2020;64(9):e01168–20.

- 482 [34] Brian C Nelson, Justin Laracy, Sherif Shoucri, Donald Dietz, Jason Zucker, Nina Patel, et
483 al. Clinical outcomes associated with methylprednisolone in mechanically ventilated
484 patients with covid-19. *Clinical Infectious Diseases*. 2021;72(9):e367–e372.
- 485 [35] Jiao Liu, Sheng Zhang, Xuan Dong, Zhongyi Li, Qianghong Xu, Huibin Feng, et al.
486 Corticosteroid treatment in severe covid-19 patients with acute respiratory distress
487 syndrome. *The Journal of clinical investigation*. 2020;130(12):6417– 6428.
- 488 [36] Linda E Levesque, James A Hanley, Abbas Kezouh, and Samy Suissa. Problem of immortal
489 time bias in cohort studies: example using statins for preventing progression of diabetes.
490 *Bmj*. 2010;340.
- 491 [37] Michele Bartoletti, Lorenzo Marconi, Luigia Scudeller, Livia Pancaldi, Sara Tedeschi,
492 Maddalena Giannella, et al. Efficacy of corticosteroid treatment for hospitalized patients
493 with severe covid-19: a multicentre study. *Clinical Microbiology and Infection*.
494 2021;27(1):105–111.
- 495 [38] Jesús Rodríguez-Baño, Jerónimo Pachón, Jordi Carratalá, Pablo Ryan, Inmaculada Jarrín,
496 María Yllescas, et al. Treatment with tocilizumab or corticosteroids for covid-19 patients
497 with hyperinflammatory state: a multicentre cohort study (sam-covid-19). *Clinical*
498 *Microbiology and Infectio*. 2021;27(2):244–252.
- 500 [39] Ivan Cusacovich, Alvaro Aparisi, Miguel Marcos, Cristina Ybarra-Falcon, Carolina
501 Iglesias-Echevarria, et al. Corticosteroid pulses for hospitalized patients with covid-19:
502 effects on mortality. *Mediators of inflammation*, 2021.
- 503 [40] Cecilia Tortajada, Enrique Colomer, Juan C Andreu-Ballester, Ana Esparcia, Carmina
504 Oltra, and Juan Flores. Corticosteroids for covid-19 patients requiring oxygen support? yes,
505 but not for everyone: effect of corticosteroids on mortality and intensive care unit admission
506 in patients with covid-19 according to patients' oxygen requirements. *Journal of Medical*
507 *Virology*. 2021;93(3):1817–1823.
- 508 [41] Gareth J Griffith, Tim T Morris, Matthew J Tudball, Annie Herbert, Giulia Mancano,
509 Lindsey Pike, et al. Collider bias undermines our understanding of covid-19 disease risk
510 and severity. *Nature communications*. 2020;11(1):1–12.

511

512

513 **Figure Captions**

514

515 Figure 1. Illustrated example of two patients under the two hypothetical treatment regimes of our
516 target trial emulation. Patient A reaches severe hypoxia criteria at study day 2 and is followed the
517 entire study duration. Patient B never reaches severe hypoxia criteria and is lost to follow up
518 after five study days. Under the dynamic corticosteroids regime (Intervention #1), Patient A
519 receives 6 days of corticosteroids, and under Intervention #2 they receive no corticosteroids.
520 Patient B does not receive corticosteroids under either treatment regime, however, in both
521 hypothetical worlds they are observed for the entire study duration.

522

523 Figure 2. Illustrative Directed Acyclic Graph (DAG) showing the relationship between
524 confounders L_t , corticosteroid exposure A_t , and mortality Y_t . Baseline confounders are included in
525 L_0 . For simplicity, loss-to-follow-up nodes are not shown. Abbreviations: BMI = Body Mass
526 Index, BUN = Blood Urea Nitrogen, ACE/ARBs = Angiotensin-converting enzyme and
527 Angiotensin receptor blockers.

528

529 Figure 3. Forest plot of model-first results. Study designs A-J correspond to Table 1's
530 specifications.

531

532 **Tables**

533 Table 1: Study design specifications for the model-first approaches.

Model	Study Design
A	Corticosteroid exposure defined as anytime during the course of hospitalization. All patients satisfying inclusion criteria are included in the analysis and time to event is defined as time from hypoxia to death.
B	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. All patients satisfying inclusion criteria are included in the analysis and time to event is defined as time from hypoxia to death.
C	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids after the time window are included in the control group.
D	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the time window are included in the control group.
E	Corticosteroid exposure defined as any administration up to one day after meeting hypoxia criteria. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the one-day time window passes are censored at the time of corticosteroids receipt.
F	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. All patients satisfying inclusion criteria are included in the analysis and time to event is defined as time from hypoxia to death.
G	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids after the time window are included in the control group.
H	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. Patients who died during this time window are excluded. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the time window are included in the control group.
I	Corticosteroid exposure defined as any administration up to five days after meeting hypoxia criteria. Patients who receive corticosteroids before hypoxia are excluded. Patients who receive corticosteroids after the one-day time window passes are censored at the time of corticosteroids receipt.
J	Corticosteroid exposure is allowed to be a time-varying covariate beginning at the time of hospitalization.

534

535

536

537

538 Table 2. Demographics and outcome for study cohort, overall and stratified by any corticosteroid
539 exposure.

Characteristic^a	Overall [N=3,298]	Corticosteroid Never [N=2,875]	Corticosteroids Ever [N=423]
Age	65 (53, 77)	65 (52, 77)	67 (58, 75)
Sex			
Female	1,328 (40%)	1,178 (41%)	150 (35%)
Male	1,970 (60%)	1,697 (59%)	273 (65%)
Race^b			
Asian	602 (18%)	517 (18%)	85 (20%)
Black	399 (12%)	352 (12%)	47 (11%)
White	938 (28%)	818 (28%)	120 (28%)
Other	1,141 (35%)	1,009 (35%)	132 (31%)
Unknown or declined	218 (6.6%)	179 (6.2%)	39 (9.2%)
Ethnicity			
Hispanic or Latinx	1,117 (34%)	994 (35%)	123 (29%)
Non-Hispanic or Latinx	1,585 (48%)	1,388 (48%)	197 (47%)
Unknown or declined	596 (18%)	493 (17%)	103 (24%)
BMI^c	27 (23, 31)	27 (23, 31)	28 (24, 32)
Home supplemental oxygen	312 (9.5%)	286 (9.9%)	26 (6.1%)
Coronary Artery Disease	460 (14%)	402 (14%)	58 (14%)


Diabetes Mellitus	1,033 (31%)	891 (31%)	142 (34%)
Hypertension	1,780 (54%)	1,544 (54%)	236 (56%)
Cerebral Vascular Event	225 (6.8%)	193 (6.7%)	32 (7.6%)
Cirrhosis	35 (1.1%)	30 (1.0%)	5 (1.2%)
CKD/ESRD	159 (4.8%)	146 (5.1%)	13 (3.1%)
Asthma	180 (5.5%)	145 (5.0%)	35 (8.3%)
COPD	134 (4.1%)	100 (3.5%)	34 (8.0%)
Active cancer	136 (4.1%)	118 (4.1%)	18 (4.3%)
Immunosuppressed	51 (1.5%)	44 (1.5%)	7 (1.7%)
ILD	5 (0.2%)	3 (0.1%)	2 (0.5%)
HIV	35 (1.1%)	33 (1.1%)	2 (0.5%)
Active smoker	104 (3.2%)	93 (3.2%)	11 (2.6%)
Former smoker	543 (16%)	442 (15%)	101 (24%)
Outcome: 28-day mortality	699 (21%)	574 (20%)	125 (30%)

^aAll continuous variables are reported as median (interquartile range) and categorical variables are n (%). Abbreviations: BMI=Body Mass Index, CKD=Chronic Kidney Disease, ESRD=End Stage Renal Disease, COPD=Chronic Obstructive Pulmonary Disease, ILD=Interstitial Lung Disease, HIV=Human Immunodeficiency Virus. ^bOther race category includes American Indian or Alaskan Native, Pacific Islander, multiracial, or a patient response of “some other race”. ^c190 (5.8 %) patients did not have BMI data available.


540

541

Naturally observed world:




Exposure:




Hypothetical Intervention #1:

Corticosteroids at severe hypoxia and no loss to follow-up



Hypothetical Intervention #2:


No corticosteroids and no loss to follow-up



Estimand:
Difference in mortality rate
Hypothetical Intervention #1 and Hypothetical Intervention #2

Study day





L: Confounders

Baseline - age, sex, race, ethnicity, BMI, comorbidities (coronary artery disease, cerebral vascular event, hypertension, Diabetes Mellitus, cirrhosis, Chronic Obstructive Pulmonary Disease, active cancer, asthma, interstitial lung disease, chronic kidney disease, immunosuppression, Human Immunodeficiency Virus infection, home oxygen use), mode of respiratory support within 3 hours of hospital admission, and hospital admission location.

Time-dependent - heart rate, pulse oximetry percentage, respiratory rate, temperature, systolic and diastolic blood pressure, BUN-creatinine ratio, creatinine, neutrophils, lymphocytes, platelets, bilirubin, blood glucose, D-dimers, C-reactive protein, Activated Partial Thromboplastin time, prothrombin time, arterial partial pressure of oxygen, and arterial partial pressure of carbon dioxide, mode of respiratory support, vasopressors, diuretics, ACE/ARBs, hydroxychloroquine, and tocilizumab.

Model Hazard Ratio (95% CI)

A 0.50 (0.41–0.62)

B 0.95 (0.66–1.37)

C 0.92 (0.63–1.33)

D 0.89 (0.56–1.41)

E 0.66 (0.41–1.04)

F 0.77 (0.60–0.99)

G 1.05 (0.77–1.45)

H 1.04 (0.75–1.45)

I 0.63 (0.48–0.83)

J 1.08 (0.80–1.47)

